Evercore ISI lowered the firm’s price target on Viridian Therapeutics (VRDN) to $26 from $27 and keeps an Outperform rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics price target lowered to $39 from $48 at Stifel
- Viridian Therapeutics Raises $359 Million in Offerings
- Viridian Therapeutics 7.353M share Spot Secondary priced at $17.00
- Viridian Therapeutics price target raised to $34 from $30 at RBC Capital
- Viridian Therapeutics: REVEAL-2 Success and Strong Cash Runway Support Buy Rating, $32 Price Target Unchanged